What question did this study set out to answer?

The aim is to evaluate urinary α1-microglobulin as a biomarker for early nephropathy in type 2 diabetic individuals.

February 1, 2003Diabetes CareOpen Access

Urinary α1-Microglobulin as a Marker of Nephropathy in Type 2 Diabetic Asian Subjects in Singapore

View Full Paper

Ask AI

Bookmark

Authors

Cross-sectional study unveils urinary α1-microglobulin's role in nephropathy, highlighting its relation to diabetes control in Asian populations.

The aim is to evaluate urinary α1-microglobulin as a biomarker for early nephropathy in type 2 diabetic individuals.
Cross-sectional study involving 590 type 2 diabetic patients from a primary care clinic.
Logged urinary α1-microglobulin levels and adjusted for urine flow variability using urine creatinine.
Data collected through patient interviews and medical records.
Urinary α1-microglobulin levels significantly correlated with diabetes duration: 1.19 mg/mmol for <10 years and 1.43 mg/mmol for ≥10 years (P = 0.07).
Levels were highest in insulin-treated patients (1.47 mg/mmol) compared to those on oral medication (1.36) and diet (0.86 mg/mmol, P = 0.01).
A notable 33.6% of patients with normoalbuminuria had raised urinary α1-microglobulin, indicating its potential as an early nephropathy marker.

Hong et al. (2003) studied this question.

View Full Paper

Ask AI

Bookmark

Cross-sectional study unveils urinary α1-microglobulin's role in nephropathy, highlighting its relation to diabetes control in Asian populations.